Abstract

Cluster headache is characterized by activation of the autonomic-trigeminal reflex. Nitric oxide can trigger headaches in patients, and nitric oxide signaling is known to be affected in cluster headache. Based on the hypothesis of nitric oxide being involved in cluster headache pathophysiology we investigated nitric oxide synthases as potential candidate genes for cluster headache. We analyzed eight variants in the three forms of nitric oxide synthase (NOS) genes, inducible NOS (iNOS), endothelial NOS (eNOS) and neuronal NOS (nNOS), and tested for association with cluster headache. Swedish cluster headache patients (n = 542) and controls (n = 581) were genotyped using TaqMan® assays on an Applied Biosystems 7500 qPCR cycler. This is the largest performed genetic study on NOS involvement in cluster headache so far. We found an association between cluster headache and one iNOS haplotype consisting of the minor alleles of rs2297518 and rs2779249 (p = 0.022). In addition, one of the analyzed nNOS variants, rs2682826, was associated with reported triptan use (p = 0.039). Our data suggest that genetic variants in NOS genes do not have a strong influence on cluster headache pathophysiology, but that certain combinations of genetic variants in NOS genes may influence the risk of developing the disorder or triptan use.

Highlights

  • Nitric oxide (NO) is a vasodilating molecule and neurotransmitter frequently discussed as a player involved in the pathophysiology of cluster headache (CH)

  • Statistic tests confirmed a weak association between this single nucleotide polymorphisms (SNPs) and CH, which did not remain after correction for multiple testing

  • Allele frequencies in endothelial NOS (eNOS) and neuronal NOS (nNOS) variants as well as rs2297518 in inducible NOS (iNOS) were distributed in CH patients and controls

Read more

Summary

Introduction

Nitric oxide (NO) is a vasodilating molecule and neurotransmitter frequently discussed as a player involved in the pathophysiology of cluster headache (CH). CH is classified as a trigeminal autonomic cephalalgia, the pathology characterized by excruciatingly painful attacks located around the eye. In active periods, these attacks occur at a frequency of one attack every other day to up to eight attacks per day. During CH attacks there is an activation of the autonomic-trigeminal reflex, where calcitonin gene-related peptide (CGRP) is released from trigeminal neurons innervating the dura mater, resulting in local inflammation and pain [3,4]. NO is involved in many of the biological processes that drive CH attacks, e.g., vasodilation, inflammation and pain signaling [5,6], and signs of elevated levels of NO activity have been detected in patients [7]. Changes in NO levels or related molecules could have an impact on CH pathophysiology

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.